Results from Prospective Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly Underdiagnosed
-- 45% (181/405) of symptomatic patients biopsied with chronic functional gastrointestinal symptoms met the histologic criteria for eosinophilic gastritis and/or eosinophilic duodenitis --
-- Management to host conference call and webcast today at 8:00 am ET --
“Millions of patients in
Prevalence Study Design
This prospective, multi-center study assessed eosinophil and mast cell levels in biopsies obtained from patients with active, chronic unexplained gastrointestinal symptoms or FGIDs. Inclusion in the study required patients to have ≥6-month history of abdominal pain, abdominal cramping, nausea, vomiting, diarrhea, bloating and/or early satiety without identifiable cause and unresponsive to pharmacologic or dietary intervention, or a diagnosis of IBS or FD. Gastric and duodenal biopsies were performed in patients who had an average weekly single symptom severity score ≥3 for abdominal pain, abdominal cramping, nausea, vomiting, diarrhea, bloating or early satiety and a total symptom severity score ≥10 as assessed by the patient reported outcome (PRO) questionnaire used in the Company’s Phase 2 (ENIGMA) and Phase 3 EG and/or EoD studies. The primary endpoints were:
- The proportion of symptomatic patients that underwent biopsy and met the histologic criteria for EG and/or EoD (≥30 eosinophils/HPF in five HPFs of the stomach or ≥30 eosinophils/HPF in three HPFs of the duodenum, respectively).
- The proportion of symptomatic patients that underwent biopsy with ≥30 mast cells/HPF in five gastric HPFs and/or ≥30 mast cells/HPF in three duodenal HPFs and <30 eosinophils/HPF, referred to as MGID.
Prevalence Study Results
73% (405 of 556) of patients screened met the symptom severity criteria and underwent endoscopy with biopsy. Of the patients biopsied, 45% (181 of 405) met the histologic criteria for EG and/or EoD, representing 33% (181 of 556). In addition, 50% (204 of 405) of patients biopsied had ≥30 mast cells/HPF and <30 eosinophils/HPF (MGID). Results are presented below:
|Entered Screening, N||556|
|Met Symptom Criteria for Biopsy, n||405|
|Met Histologic Criteria for EG/EoD¹, n (%)||181/405 (45%)|
|Met Histologic Criteria for MGID², n (%)||204/405 (50%)|
|Neither, n (%)||20/405 (5%)|
¹ Patients with ≥30 eosinophils/high powered field (HPF) in five gastric HPFs and/or ≥30 eosinophils/HPF in three duodenal HPFs
² Patients ≥30 mast cells/HPF in five gastric HPFs and/or ≥30 mast cells/HPF in three duodenal HPFs; <30 eosinophils/HPF
Conference Call and Live Webcast
The Company will host a conference call and webcast with slides today at
About Eosinophilic Gastritis and Eosinophilic Duodenitis
Eosinophilic gastritis and eosinophilic duodenitis (previously referred to as eosinophilic gastroenteritis) are chronic, often severe, inflammatory diseases characterized by persistent gastrointestinal symptoms and elevated and activated eosinophils in the stomach and/or, duodenum, respectively. Emerging data suggests that activated mast cells also contribute to disease pathogenesis. Common symptoms include abdominal pain, nausea, diarrhea, bloating, cramping, early satiety, loss of appetite, vomiting and weight loss. Published literature reports the prevalence of eosinophilic gastritis and eosinophilic duodenitis in the United States to be approximately 50,000 people. The Company believes that these diseases may be significantly underdiagnosed or misdiagnosed as other gastrointestinal diseases. The results from this study suggest that EG and/or EoD may be more common than documented in the literature. There are no treatments approved specifically for these diseases. Treatment with systemic steroids can provide symptomatic improvement, however, long-term treatment with steroids is generally not possible due to the numerous side effects.
About Lirentelimab Development in EG and/or EoD
Lirentelimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Lirentelimab has been studied in a prospective, multi-center, randomized, double-blind, placebo controlled, Phase 2 Study in patients with EG and/or EoD (ENIGMA). In ENIGMA, all lirentelimab dose arms showed clinically meaningful and statistically significant benefits when compared to placebo across all prespecified primary and secondary endpoints, including reductions in gastrointestinal tissue eosinophil counts and patient-reported disease symptoms. Detailed results were published in the
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, Allakos’ progress and business plans, the expected timing of anticipated study results and plans relating to its future clinical trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: Allakos’ stages of clinical drug development; Allakos’ ability to timely complete clinical trials for, and if approved, commercialize lirentelimab (AK002), its lead compound; Allakos’ ability to obtain required regulatory approvals for its product candidates; uncertainties related to the enrollment of patients in its clinical trials; Allakos’ ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties related to the success of later-stage clinical trials, regardless of the outcomes of preclinical testing and early-stage trials; market acceptance of Allakos’ product candidates; uncertainties related to the projections of the size of patient populations suffering from the diseases Allakos is targeting; Allakos’ ability to advance additional product candidates beyond lirentelimab; Allakos’ ability to obtain additional capital to finance its operations; and other important risk factors set forth in Allakos’ most recent Annual Report on Form 10-K filed with the SEC on February 25, 2020, Quarterly Report on Form 10-Q filed with the SEC on August 10, 2020 and future reports to be filed with the SEC. These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos’ forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Allakos specifically disclaims any obligation to update any forward-looking statement, except as required by law. These forward-looking statements should not be relied upon as representing Allakos’ views as of any date subsequent to the date of this press release.
Adam Tomasi, President and COO email@example.com Media Contact: Denise Powelldenise@redhousecomms.com
Source: Allakos Inc.